
Tirzepatide vs. Semaglutide for Women: What 2025-2026 Trial Data Shows
Tirzepatide vs semaglutide for women: trial data through 2025-2026 shows tirzepatide (Mounjaro/Zepbound) produces greater mean weight loss in women, averaging 22.5% of body weight at 72 weeks versus 14.9% for semaglutide 2.4 mg (Wegovy) at 68 weeks in their respective…













